Evotec AG is a drug discovery alliance and development partnership company focused on progressing product approaches with pharmaceutical and biotechnology companies.The company's headquarters are located in Hamburg, Germany. It operates worldwide providing integrated drug discovery solutions, covering all activities from target-to-clinic.Evotec employs over 500 scientists and works in key therapeutic areas including CNSAstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development.In fiscal year 2013, Evotec generated revenues of €85.94 m. At the end of September 2014, Evotec had 718 employees.Since 28 October 2009 the company is listed in the TecDAX index. Wikipedia.
Evotec | Date: 2014-11-28
This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R^(1 )and R^(2 )are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
Barton P.,University of Nottingham |
Drug Discovery Today | Year: 2016
Improving the efficiency of drug discovery remains a major focus for the pharmaceutical industry. Toxicity accounts for 90% of withdrawals and major early-stage terminations relate to suboptimal efficacy and safety. Traditional oral drug space is well defined with respect to physicochemical properties and ADMET risks but increased focus on ligand-lipophilicity efficiency, maximizing enthalpy contributions and new target classes challenge this paradigm. A hybrid space has been identified that combines physical properties and key interactions attributable to drug transporters. A novel algorithm is proposed that incorporates drug-transporter interactions and its utility evaluated against popular ligand efficiency indices. Simply reducing the bulk properties of compounds can exchange one problem for another and creates high-risk areas that challenge the successful delivery from a balanced portfolio. © 2015 Published by Elsevier Ltd.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.51M | Year: 2013
Brain disorders comprise a major burden for the society. Recent analyses of the neuropsychiatric disease-related gene polymorphisms as well as genomics and proteomics have identified the components of the extracellular matrix (ECM) and the cell adhesion molecules (CAMs) in the brain as pivotal for those diseases. The ECM/CAMs span the synaptic cleft and regulate the synaptic dynamics. Furthermore, recent studies have shown that proteolytic activity may release from the ECM/CAMs cryptic ligand(s) that activate cell surface receptors and initiate intracellular signalling cascade(s). Thus, ECM and its enzymatic modifications have emerged as a highly topical research area, also because their extracellular localization makes the development of enzymatic inhibitors more feasible. This proposal brings together a group of well-established academic and industrial partners sharing interest in the ECM and its proteolysis. In the proposal there is clearly an overlapping interest in specific brain conditions and structures to be investigated, making the consortium ideally suited to provide a comprehensive picture for the role of ECM proteolysis in brain function and dysfunctions. While the academic partners focus on specific research questions, the industrial members are to provide the entire consortium with high-throughput techniques and powerful research tools. This combination of conceptual scientific vision, tools and approaches should be of great benefit for the young researchers to be trained. The trainees will be exposed to courses, workshops, joint research meetings and inter-laboratory visits. The focus of the training program is on expanding knowledge and on developing new treatments to anxiety disorders, schizophrenia, mental retardation and Alzheimers. A unifying neurobiological concept in the consorted effort to tackle these conditions is the involvement of abnormal synaptic plasticity.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-5-2015 | Award Amount: 4.94M | Year: 2016
This Centre of Excellence will advance the role of computationally based modelling and simulation within biomedicine. Three related user communities lie at the heart of the CoE: academic, industrial and clinical researchers who all wish to build, develop and extend such capabilities in line with the increasing power of high performance computers. Three distinct exemplar research areas will be pursued: cardiovascular, molecularly-based and neuro-musculoskeletal medicine. Predictive computational biomedicine involves applications that are comprised of multiple components, arranged as far as possible into automated workflows in which data is taken, from an individual patient, processed, and combined into a model which produces predicted health outcomes. Many of the models are multiscale, requiring the coupling of two or more high performance codes. Computational biomedicine holds out the prospect of predicting the effect of personalised medical treatments and interventions ahead of carrying them out, with all the ensuing benefits. Indeed, in some cases, it is already doing so today. The CoE presents a powerful consortium of partners and has an outward facing nature and will actively train, disseminate and engage with these user communities across Europe and beyond. Because this field is new and growing rapidly, it offers numerous innovative opportunities. There are three SMEs and three enterprises within the project, as well as eight associate partners drawn from across the biomedical sector, who are fully aware of the vast potential of HPC in this domain. We shall work with them to advance the exploitation of HPC and will engage closely with medical professionals through our partner hospitals in order to establish modeling and simulation as an integral part of clinical decision making. Our CoE is thus user-driven, integrated, multidisciplinary, and distributed; presenting a vision that is in line with the Work Programme.
Evotec | Date: 2015-09-30
The present invention relates to the preparation of compounds of formula (I)^(1), R^(2), R^(2a), R^(3), X^(1) to X^(3) have the meaning as indicated in the description and claims and to intermediate compounds used to prepare compounds of formula (I).
Evotec | Date: 2014-04-03
The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.
Evotec | Date: 2014-05-27
The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
Evotec | Date: 2015-04-08
The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
Evotec | Date: 2013-11-07
The invention relates to compounds of formula (I) wherein R^(1), R^(1a), R^(1b), R^(2), R^(3 )and X, X^(1), X^(2), X^(3 )have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
Evotec | Date: 2013-02-22
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.